Prediabetes is generally associated with glucose levels which are above normal but fall below the defined threshold for diabetes. In addition to likely progression to diabetes, prediabetes can put some people at greater risk for various health problems and complications. Given these risks and the often-asymptomatic nature of prediabetes, there is an increasing need to better understand the epidemiological and economic burden for more effective policy and action.
To address this need, the EIU conducted a research programme to illuminate the costs of inaction around prediabetes in Hong Kong, as well as the potential economic impact of interventions to delay the onset of type 2 diabetes (T2DM).
Several key experts and stakeholders were engaged in the process. To note, the findings and views expressed in this report are those of EIU Healthcare and do not necessarily reflect the views of these contributors or project sponsors. We extend our sincere appreciation to the following for their time and contributions to this work:
• Dr Andrea Luk, Associate Professor, Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong
• Dr Quan Chao, Clinical Assistant Professor, School of Public Health, University of Hong Kong
• Dr Peter Tong, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong
This work was commissioned by Merck Pharmaceutical and conducted independently by the EIU. The research was led by Gerard Dunleavy, with guidance from Rohini Omkar and Rob Cook. The economic modelling was performed by Dustin Hamalainen. The report was written by Amrita Namasivayam, and edited by Gerard Dunleavy and Rohini Omkar. André Comiran Tonon and Jocelyn Ho were contributing researchers.
